Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER) long-term follow-up results from an open-label, randomised, phase 3 trial

Motzer, Robert J.; Powles, Thomas; Burotto, Mauricio; Escudier, Bernard; Bourlon, Maria T.; Shah, Amishi Y.; Suarez, Cristina; Hamzaj, Alketa; Porta, Camillo; Hocking, Christopher M.; Kessler, Elizabeth R.; Gurney, Howard; Tomita, Yoshihiko; Bedke, Jens; Zhang, Joshua; Simsek, Burcin; Scheffold, Christian; Apolo, Andrea B.; Choueiri, Toni K.

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER) long-term follow-up results from an open-label, randomised, phase 3 trial

Autor(en):

Motzer, Robert J.; Powles, Thomas; Burotto, Mauricio; Escudier, Bernard; Bourlon, Maria T.; Shah, Amishi Y.; Suarez, Cristina; Hamzaj, Alketa; Porta, Camillo; Hocking, Christopher M.; Kessler, Elizabeth R.; Gurney, Howard; Tomita, Yoshihiko; Bedke, Jens; Zhang, Joshua; Simsek, Burcin; Scheffold, Christian; Apolo, Andrea B.; Choueiri, Toni K.

Tübinger Autor(en):

Bedke, Jens

Erschienen in:

Lancet Oncology (2022), Bd. 23, H. 7, S. 888-898

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S1470-2045(22)00290-X

ISSN:

1470-2045